Objective: To validate glomerular filtration rate (GFR) estimating equations in white HIV-infected patients based on serum creatinine and/or serum cystatin C.
Introduction
An accurate tool for estimating glomerular filtration rate (GFR) in HIV-infected patients is both necessary and challenging. It is necessary because some of the most active antiretroviral drugs are either nephrotoxic and/or undergo a renal metabolism that requires dosage adjustment in case of decreasing GFR [1] . Likewise, a reliable evaluation of GFR is critical for the detection of chronic kidney disease (CKD) and its related complications which are becoming particularly prevalent in those patients [2, 3] . In the meantime, estimating renal function remains challenging mainly due to the fact that serum creatinine (Scr), as a GFR marker, is likely to be suboptimal in those patients prone to alteration and variation of their muscle mass [4] .
Current guidelines of the Infectious Disease Society of America recommend the use of the Modification of Diet in Renal Disease (MDRD) study equation for estimating GFR in HIV-infected patients [5] . This equation is, however, known to underestimate the true level of renal function in patients with normal or close-to-normal GFR values [6, 7] . The use of this equation is thus problematic for the detection of CKD and often leads to overdiagnosis [8, 9] . The CKD-Epidemiology Collaboration (CKD-EPI) equation has been specifically developed to correct the GFR underestimation induced by the MDRD study equation [10] . Several, but not all, studies have demonstrated that this equation offers better performance than the MDRD study equation [11] [12] [13] .
Another step toward the amelioration of the GFR evaluation is to turn to a more reliable marker of GFR than Scr. Serum cystatin C (Scyst) has the potential to circumvent many of the shortcomings of Scr and has long been proposed as a promising GFR biomarker [14] . Additionally, new drugs interfering with tubular secretion of Scr (e.g. dolutegravir and cobicistat) are becoming available [15, 16] . In this context, GFR estimation based on Scyst might be clinically useful. Thus far, a thorough evaluation of Scyst has, however, been hampered by the absence of standardization for Scyst measurement. Very recently, a certified reference material has been characterized and developed for Scyst [17] , making traceability and standardization of Scyst measurement possible. Two equations specifically developed in order to be used with standardized Scyst, have been validated in a large population: the Scyst-based CKD-EPI equation (CKD-EPI Scyst) -incorporating Scyst alone -and the Scyst/ Scr-based CKD-EPI equation (CKD-EPI combined) [18] .
In HIV-infected patients, a few studies -with contradictory results -have sought to evaluate whether alternative Scyst and/or Scr-based equations might improve GFR estimation in comparison to the MDRD study equation [19] [20] [21] [22] [23] [24] . All these studies, however, had limitations [4] . Very recently, Inker et al. [25] reported that the CKD-EPI equation along with the two new equations based on Scyst were all significantly more accurate than the MDRD study equation in a cohort of 200 HIV-positive patients. Importantly, while it is so far the only study that has used calibrated Scr and Scyst, the Inker et al. study has exclusively enrolled North American patients. Given the well known differences in ethnicity, body composition, conditions of HIV acquisition and prevalence of viral co-infection, their findings do not necessarily extend to non-US populations.
Using standardized measures and similar methodology, we thus studied the performance of these new CKD-EPI equations with the aim of recommending the most appropriate equation for practitioners taking care of HIV-infected patients in Europe.
Patients and methods

Study population
Patients were recruited from the department of infectious diseases of the University Hospital of Saint-Etienne (France). Eligible patients were 18 years old, with confirmed HIV status. Exclusion criteria were pregnancy, history of allergy, thyroid dysfunction, recent acute kidney injury, and treatment by metformin, steroids, trimethoprim, or cimetidine. The protocol was submitted and approved by Saint-Etienne's Hospital Institutional Review Board. The study was conducted in full compliance with the amended declaration of Helsinki following approval from the local ethical committee.
Glomerular filtration rate measurement Glomerular filtration rate measurements were based on plasma clearance of iohexol (Omnipaque 300 GE Healthcare). After administration of 10 ml of iohexol intravenously, two blood samples were collected at approximately 120 and 240 min with exact time recorded. Iohexol plasma concentration was determined by high-performance liquid chromatography and mass spectrometry [26] . GFR was calculated using previously described protocol [27] . Measured GFR was reported to body surface area (BSA) as estimated by the Dubois & Dubois formula [28] .
Laboratory methods
Blood and urine samples were stored at À808C. Scr was measured by IDMS-traceable enzymatic method [Orthoclinical diagnostics, United Kingdom, coefficient of variation (CV) 5.6% at 0.71 mg/dl, and 2.1% at 5.82 mg/dl]. Scyst was measured by IFCC-traceable (International Federation of Clinical Chemistry) nephelometric method (Siemens, Germany) on a Siemens BN Prospec analyzer (CV of 2.9% at 1.03 mg/l and 2.1% at 1.93 mg/l) [17] . HIV viral load was determined by Abbott m2000 real-time HIV-1 assay (Abbott Diagnostics, France). The CD4 þ lymphocyte count was measured by flow cytometry at the time of GFR measurement. Urine microalbumin was determined by immunonephelometry on a Siemens BN ProSpec. Sensitivity of the assay is 0.16 mg/dl with inter-assay CVs of 3.0%.
Data collection
Clinical variables collected at the time of GFR measurement were sex, age, height, weight, time since HIV-infection diagnosis, history of injecting drug use, smoking status, history of hypertension, dyslipidemia and/or diabetes mellitus, highly active anti-retroviral therapies (HAART) regimen, hepatitis B virus and hepatitis C virus status, liver cirrhosis. In the study, diabetes mellitus was defined as a diagnosis of diabetes mellitus prior to the study or use of oral antidiabetic agents or insulin at the time of enrollment. Hypertension was defined as SBP above 140 mmHg, DBP above 90 mmHg or the use of antihypertensive agents. Dyslipidemia was defined as triglycerides greater than 2 g/l or use of fibrates at the time of enrollment, or lowdensity lipoprotein cholesterol greater than 1.60 g/l or use of statins at the time of enrollment.
Biological variables collected at the time of GFR measurement were HIV viral load, CD4-positive lymphocyte count, C-reactive protein (CRP), urinary albumin/creatinine ratio (ACR), serum Scyst and Scr.
Analysis of the performance of glomerular filtration rate estimating equations and statistics Glomerular filtration rate was estimated with the MDRD study equation [29] , the CKD-EPI equation [10] , the CKD-EPI Cys equation and the CKD-EPI combined equation [18] (Table 1) . We considered the AfricanAmerican coefficient factor as not applicable to black participants from Africa, Europe or Antilles [30] .
Simple linear regression was used to calculate the Pearson's correlation coefficients between measured GFR (mGFR) and estimated GFR (eGFR) by the four equations.
The predictive performance of the four GFR estimates was assessed with the following parameters:
(1) Absolute bias, defined as the mean difference between eGFR and mGFR, a negative value meaning that eGFR under-estimates true GFR. (2) Relative bias, calculated as absolute bias/mGFR Â 100 (3) Precision, evaluated by the standard deviation of the mean difference between eGFR and mGFR (absolute and relative) (4) Accuracy, defined as the proportion of eGFR values within AE30% of the mGFR. (5) Agreement, evaluated by the Bland and Altman method [31] .
The relative performance of the GFR estimating equations was evaluated by comparing the precision using F-test and the accuracy using GraphPad Prism 6 (GraphPad Software, La Jolla, California, USA).
Results
Two hundred and five HIV-infected patients were enrolled between February 2011 and June 2012. Two of them were excluded from the analysis because one was a kidney transplant recipient and because the iohexol protocol was corrupted in the second one. Characteristics are summarized in Table 2 . Mean age was 49 AE 10 years, 18% of patients were female. Mean BMI was 24 AE 4 kg/m 2 and 93% of the patients were white. Most patients were receiving HAART and had undetected HIV viral load at the time of GFR measurement (93% and 83%, respectively). HAART regimen contained tenofovir in 55% of the patients. History of diabetes mellitus and hypertension was present in 6 and 18% of the patients, respectively. Evidence for proteinuria (defined as ACR >30 mg/g) was found in 39 patients (19%). Mean measured GFR was 95 AE 24 ml/min per 1.73 m 2 . Fiftyeight percent (n ¼ 118) of the patients had mGFR greater than 90 ml/min per 1.73 m 2 and only 9% (n ¼ 18) had mGFR less than 60 ml/min per 1.73 m 2 .
Considering the whole study population (Table 3 and Fig. 1 Performances of the equation (bias, precision and accuracy) strongly varied according to the GFR levels (Table 4) . Whereas these performances were clearly insufficient in patients with mGFR under 60 ml/min per 1.73 m 2 , they were globally better above this cut-off. This was especially true for patients with mGFR between 90 and 120 ml/min per 1.73 m 2 (accuracy between 87 and 99%). In this GFR range, the accuracy of the MDRD equation remained significantly inferior as compared to the three other equations ( 
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Values expressed as mean AE SD (range) or number (percentage). ACR, urinary albumine/creatinine ratio; GFR, glomerular filtration rate. Table 3 . Predictive performances of the MDRD study, CKD-EPI, CKD-EPI-Scyst, and CKD-EPI-combined equations in HIV patients (n U 203). reclassification of patients around the threshold of 60 ml/ min per 1.73 m 2 (Table 5 ). 
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Discussion
Estimating GFR in HIV patients is now recommended [5] as these patients seem at higher risk for CKD [1, 2, 4] . In our cohort of European patients, we studied the performance of the most recent Scr and Scyst-based equations [10, 18, 29] . Considering the whole population, we demonstrate that the CKD-EPI equation has a better accuracy than the MDRD study equation.
Regarding the new Scyst-based equations, we show that none of them provide a more accurate estimation than the CKD-EPI equation. We thus confirm, for the first time in European patients, that the CKD-EPI equation should be the equation of first choice in the HIV-infected population. [10, 25] . This result is not unexpected as the vast majority of our patients had normal or high mGFR [10, 13, 18] . As compared to data recently published in the general population, the performance of both the CKD-EPI Scyst and the CKD-EPI combined equation is somewhat disappointing. However our findings are consistent with other data obtained from another HIV cohort [25] . Several hypotheses can be drawn to explain the lack of advantage for Scyst in those patients. Many factors have indeed been proposed to influence Scyst levels independently of any GFR change, as inflammation and tobacco for instance [14, [32] [33] [34] . More specifically, it has been suggested that HIV viral load could also influence Scyst levels [35, 36] . In our cohort, accuracies are similar for the three equations in the group of smokers in comparison with the nonsmokers. However, we observe a trend for a better accuracy of the CKD-EPI as compared to the CKD-EPI Scyst in patients with detectable HIV viral load.
Performances of the four equations were particularly poor in patients with GFR under 60 ml/min per 1.73 m 2 . This observation is at odds with what is usually reported in the general population where the predictive performance of equations usually improves with decreasing GFR [29] . Here again, the same observation was previously made in HIV-infected patients [25] . Our observation was consistent with this previous study and further suggests the difficulty in accurately evaluating renal function in HIVinfected patients, a population with specific characteristics that make it different from the general population in many regards. These patients with lower mGFR are probably the patients who are frailer, notably in term of muscular mass (they were, in our cohort, older than patients with mGFR >60 ml/min per 1.73 m 2 , data not shown).
In the context of CKD screening, it is particularly important to assess the performance of the equation 'around' 60 ml/min per 1.73 m 2 which is considered as the 'threshold' value for CKD diagnosis by several, but not all, authors [37, 38] . In this view, the rather good results observed when considering the whole population must here again be tempered. In the subgroup of mGFR between 60 and 90 ml/min per 1.73 m 2 , a subgroup which is both clinically and quantitatively important, all the equations -even the CKD-EPI equation -exhibit suboptimal performance with accuracy below 80%.
To the best of our knowledge, only the study recently published by Inker et al. [25] has used calibrated Scyst and Scr. In this study, the authors studied the performances of the MDRD, CKD-EPI, CKD-EPI Scyst and CKD-EPI combined equations in 200 HIV patients from USA [25] . Interestingly, they measured, like us, GFR with iohexol plasma clearance. Some limitations of our study must be considered. The study population includes only few patients with mGFR under 60 ml/min per 1.73 m 2 . Results observed in the subgroup of low GFR must thus be considered with caution. Our patients are almost exclusively white. Only 15 patients were identified as blacks (of note, no ethnic coefficient was specifically used for those patients). For patients with marked renal impairment (less than 10% of our study population), an additional and later measurement of iohexol is usually recommended but was not performed in our study. Finally, since very few patients were not receiving HAART and had a detectable HIV viral load, our results cannot be extrapolated to all HIVinfected patients.
In conclusion, we demonstrate that the CKD-EPI equation outperforms the MDRD study equation in European HIV-infected patients. Recent equations including standardized Scyst values do not provide any advantage in this population. The current guidelines regarding the preferential utilization of the CKD-EPI equation in the general population are thus also valid for estimating renal function of HIV-infected patients in the US as well as in Europe. Clinicians must however keep in mind that the estimation of renal function provided by the CKD-EPI equation remains probably suboptimal for HIV-positive patients with decreased GFR.
